Another promising possibility in treating advanced ccRCC would be the combination of epigenetic drugs and modern immunotherapy using antibodies that block programmed cell death protein 1 (PD1) and its ligands [234]. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.